HELP:NASDAQ
Cybin Inc
US$5.31
arrow_upward
+8.15%(+0.40) 1D
US$5.35
arrow_upward
+0.75% (+0.040)todayපූර්ව-වෙළඳපොළ
වසා ඇත: බක් 30, 16.00.01 ග්රිමවේ-4 · USD
search
සියලු සංකේත
1D
5D
1M
6M
YTD
1Y
5Y
උපරි
| සංකේතය | මිල | වෙනස් කිරීම | % වෙනස |
|---|
insights_autoHELP සඳහා ඉහළම ඇතුළාන්තයන් උත්පාදනය කරමින්...
විවෘත කරන්න
US$4.97
ඉහළ
US$5.33
පහළ
US$4.92
දළ පරිමාව
මි1.13
හඬ පරිමාණය
323.00
සති-52 ඉහළ
US$8.97
සති-52 පහළ
US$4.29
බීටා
1.03
ගෙවිය යුතු කොටස්
මි50.04
සේවකයින් ගණන
50
පුවත් සහ කථා
වෙබය හරහා මූලාශ්ර වෙතින්
TipRanks
·
පැය 13කට පෙර
Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference
Stock Titan
·
පැය 22කට පෙර
A Milken health-innovation panel will feature Helus Pharma's interim CEO
Investing.com
·
දින 2කට පෙර
Helus Pharma partners with TARA Mind for trial recruitment
පැතිකඩ
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Cybin Inc ගැන
AI අන්තර්ගතයේ වැරදි ඇතුළත් විය හැක. තව දැන ගන්න